Journal Information
Vol. 22. Num. 1.January - February 2018
Pages 1-78
Download PDF
More article options
Vol. 22. Num. 1.January - February 2018
Pages 1-78
Letter to the Editor
DOI: 10.1016/j.bjid.2017.10.001
Open Access
Is it time for Brazil to prioritize TB preventive therapy for all people living with HIV?
Ethel L. Maciela,
Corresponding author

Corresponding author.
, Thiago N. do Pradoa, Kleydson Bonfim Andradeb, Jonathan E. Golubc
a Universidade Federal do Espírito Santo (UFES), Laboratório de Epidemiologia (Lab-Epi), Vitória, ES, Brazil
b Universidade de São Paulo, Faculdade de Saúde Pública, São Paulo, SP, Brazil
c Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Baltimore, United States
This item has received

Under a Creative Commons license
Article information
Full Text
Download PDF
Dear Editor:
Full Text

People living with HIV (PLWH) in Brazil have a tuberculosis (TB) cure rate of 49.1%, while preventive therapy for latent tuberculosis infection (LTBI) is vastly underutilized in this high-risk population. Historically, the Brazilian TB control program's primary focus is similar to all other high burden settings, emphasizing diagnosis and treatment of active disease with little energy is expended toward contact investigations and preventive therapy.1

Brazilian guidelines recommend isoniazid preventive therapy (IPT) for 6 months using a dose of 300mg/day, but only for PLWH and adult and child household contacts who have a positive tuberculin skin test (TST).1 A cluster randomized trial2 showed that offering TST and IPT, as per Brazilian guidelines, significantly reduced TB risk and mortality among PLWH, however almost 40% of patients never received a TST, thus limiting impact of the intervention.2 A follow-up study decisively reported that patients receiving IPT had long-term protection from TB.3 In 2006, a preventive therapy regimen of rifapentine plus isoniazid given once weekly for three months (3HP) was shown to be effective in Brazil.4 More recently, 3HP proved as effective as isoniazid alone in a multi-country study, including Brazil, for people living with5 and without HIV.6 Based on this evidence, the Brazilian NTP has initiated the process of incorporating the 3HP regimen.

The National TB and AIDS programs have worked independently for decades. However, the programs have improved communications in recent years and are developing collaborative actions focused on LTBI in PLWH. A more effective and efficient approach would see the AIDS program take responsibility for IPT as they have for other disease prevention,7,8 and the development of surveillance system for notification and monitoring of cases of latent TB, the latter of which is currently in development.

Finally, Brazil is facing the global shortage of tuberculin,9 thus few TSTs are available country-wide, leading to alternate, but more expensive approaches to diagnosing latent TB, including interferon gamma release assays. If barriers exist toward diagnosing LTBI, then Brazil must consider moving toward universal LTBI treatment for PLWH, or targeting particular high-risk subgroups among this population who are at high risk of progression to disease. A modified strategy would initiate preventive therapy for all PLWH unless a negative test for LTBI was known, and halt treatment if and when a negative test is determined. Thus, PLWH who have no history of an LTBI test, the overwhelming majority of PLWH in Brazil, would initiate preventive therapy. Such a policy shift could lead to substantial reductions in disease incidence and will certainty improve TB control toward the 2035 WHO targets.

Conflicts of interest

The authors declare no conflicts of interest.

Ministério da Saúde (BR)
Secretaria de Vigilância em saúde. Manual de recomendações para o controle da tuberculose no Brasil
B. Durovni, V. Saraceni, L.H. Moulton
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial
Lancet Infect Dis, 13 (2013), pp. 852-858
J.E. Golub, S. Cohn, V. Saraceni
Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study
Clin Infect Dis, 60 (2015), pp. 639-645
M. Schechter, R. Zajdenverg, G. Falco
Weekly rifapentine/isoniazid or dail rifampin/pyrazinamide for latent tuberculosis in household contacts
Am J Respir Crit Care Med, 173 (2006), pp. 922-926
(Epub ahead of print)
T.R. Sterling, N.A. Scott, J.M. Miro, Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17
AIDS, 30 (2016), pp. 1607-1615
T.R. Sterling, M.E. Villarino, A.S. Borisov, TB Trials Consortium PREVENT TB Study Team
Three months of rifapentine and isoniazid for latent tuberculosis infection
N Engl J Med, 365 (2011), pp. 2155-2166
Ministério da Saúde (BR)
Departamento de DST, Aids e Hepatites Virais. O Manejo da Infecção pelo HIV na Atenção Básica: Manual para profissionais médicos
Departamento de DST, Aids e Hepatites Virais, (2015)
V. Saraceni, A.G. Pacheco, J.E. Golub
Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil
Braz J Infect Dis, 15 (2011), pp. 249-252
Coordenação Geral do Programa Nacional de Controle da Tuberculose, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis, Ministério da Saúde. Ofício Circular no 25/CGPNCT/DEVIT/SVS/MS. Dificuldades na aquisição do derivado proteico purificado – PPD. [accessed 11.05.17].
Copyright © 2017. Sociedade Brasileira de Infectologia
The Brazilian Journal of Infectious Diseases

Subscribe to our Newsletter

Article options
Cookies policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.